Insmed Stock Soars After Successful Lung Disease Drug Trial
TL;DR
Insmed's experimental drug brensocatib successfully reduced lung problems in bronchiectasis patients during a Phase 3 trial, leading to a significant increase in the company's share price. Both tested dosages of the drug met the primary endpoint by reducing pulmonary exacerbations by about 20% compared to placebo, with analysts predicting potential billion-dollar annual sales if approved.
Topics:businesshealthpharmaceuticals#brensocatib#bronchiectasis#healthpharmaceuticals#insmed#phase-3-trial#stock-surge
- Insmed lung disease drug hits target in key Phase 3 trial STAT
- Insmed Stock Surges on Trial Win for Lung-Condition Drug, a Possible Blockbuster Barron's
- Insmed Stock More Than Doubled in Value Tuesday—Here's Why Investopedia
- Insmed Stock Catapults On Its Humira-Like Potential In Lung Disease Investor's Business Daily
- Insmed’s stock should triple after positive drug trial data, analyst says MarketWatch
Want the full story? Read the original reporting
Read on STAT